| Name | Title | Contact Details |
|---|---|---|
Brian Stoup |
Director of Talent Acquisition | Profile |
Michael McGarrity |
Chief Executive Officer, Executive and Managing Director | Profile |
Founded in 2010, Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies.
Medarray is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Arkuda Therapeutics is a biotechnology company applying insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda`s lead program ARKD-104 aims to correct progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene. The company is further exploring the therapeutic potential of its molecules in other neurodegenerative diseases where genetic links to dysfunction in progranulin biology have been established, including Alzheimer`s Disease and Parkinson`s Disease. Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pfizer Ventures, funds managed by Tekla Capital Management LLC, Mission BioCapital, and Eli Lilly and Company.